Kilitch Drugs (India) Limited Stock Price Today (NSE: KILITCH)

Kilitch Drugs (India) Limited

188.821.38 (0.73%)
Market Closed

Fundamental Score

...

Kilitch Drugs (India) Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Kilitch Drugs (India) Limited share price today is 188.82, down 0.73% on NSE/BSE as of 16 September 2026. Kilitch Drugs (India) Limited (KILITCH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 660.14 (Cr). The 52-week high for KILITCH share price is 219.50 and the 52-week low is 117.25. At a P/E ratio of 15.06x, KILITCH is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.52% and a debt-to-equity ratio of 0.32.

Kilitch Drugs (India) Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
199.59
Low
156.00
Volume
35.4K
Change
-1.95%

Kilitch Drugs (India) Limited share price chart: -1.95% return over the past month. 52-week high ₹219.50, 52-week low ₹117.25.

Kilitch Drugs (India) Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
190.90191.80186.00188.829.19K (Cr)
187.00194.00185.00190.2028.65K (Cr)
185.03189.90180.00185.9722.61K (Cr)
188.00190.00181.50185.0310.19K (Cr)
185.02190.01182.50188.4516.97K (Cr)
192.00192.00181.30187.8833.10K (Cr)
181.00188.00181.00187.8247.53K (Cr)
172.80181.14172.80180.9533.16K (Cr)
167.00173.71167.00172.528.77K (Cr)
170.60172.40166.15171.3725.94K (Cr)

Kilitch Drugs (India) Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
175.50194.00166.15188.82+7.59%
192.00199.59156.00174.64-9.04%
195.81207.77168.00186.59-4.71%
184.99199.99164.80194.73+5.27%
154.02197.00145.50182.39+18.42%
126.00163.40122.91154.02+22.24%
160.00165.00117.25124.45-22.22%
169.50203.00155.55161.75-4.57%
173.43184.10154.30156.98-9.49%
171.50186.95160.57175.10+2.10%
195.40201.38169.23171.05-12.46%
169.02219.50168.88194.18+14.88%

Returns & Performance

Poor

Return on Equity (ROE)

12.52%

Profit generated per ₹1 of shareholder equity

Average

Return on Capital (ROCE)

15.66%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

15.29%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Kilitch Drugs (India) Limited Valuation Check

Excellent

Price to Earnings (P/E)

15.06x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

63.77%

% shares held by company founders/management

Poor

FII Holding

0.12%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-3.73%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

4.03%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

28.00%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

30.32%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

52.39%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.32x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

7.95x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-116.51 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Kilitch Drugs (India) Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of KILITCH across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Excellent ROCE Performance (15.66%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (15.29%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 15.06 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Consistent Growth Track Record (28.00% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (30.32% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (52.39% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Interest Coverage (7.95x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 2.06)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Balanced Promoter Holding (63.77%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Negative Free Cash Flow (₹-116.51 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 0.12%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Kilitch Drugs (India) Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Kilitch Drugs (India) Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
72.6/100
189
₹660.14
15.1
Average
12.52%
Average
15.66%
Good
0.3
Excellent
52.39%
Excellent
28.00%
Excellent
0.00%
66.4/100
1865
₹447445.46
37.0
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9488
₹251432.00
86.1
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112514.52
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1363
₹110118.03
32.7
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1937
₹104646.43
95.6
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1699
₹97754.71
26.5
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96022.50
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95607.50
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2265
₹93544.50
45.8
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Kilitch Drugs (India) Limited PE Ratio History

Historical price-to-earnings ratio for KILITCH — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202516.60₹175.1010.5x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Kilitch Drugs (India) Limited Dividend History

Annual cash dividends paid by KILITCH — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 20221.20 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Kilitch Drugs (India) Limited Quarterly Performance

Latest quarterly metrics for KILITCH — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

4.03%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-3.73%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

28.00%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

52.39%

Compounded annual net profit growth over 5 years

Kilitch Drugs (India) Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for KILITCH — calculated from daily price history

88RSI 14
Overbought — RSI 88

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
181
▲ Price above SMA 50 — Short-term bullish
SMA 200
170
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
32K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Kilitch Drugs (India) Limited Financial Statements

Annual income statement, balance sheet and cash flow for Kilitch Drugs (India) Limited (KILITCH) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Kilitch Drugs (India) Limited

Loading latest quarterly results...

About KILITCH (Kilitch Drugs (India) Limited)

Kilitch Drugs India Ltd is a pharmaceutical enterprise carving a distinct niche in the global healthcare landscape. Focused on manufacturing and distributing a diverse portfolio of... specialized medications, Kilitch is committed to addressing critical healthcare needs worldwide. The company’s core strength lies in its state-of-the-art manufacturing facilities, meticulously designed to adhere to the stringent international quality standards. This focus enables the production of high-quality pharmaceuticals that are both safe and efficacious. Kilitch Drugs leverages its technical prowess and in-depth understanding of pharmaceutical science to deliver innovative solutions across various therapeutic segments. The company’s unwavering dedication to quality and its global reach positions it as a reliable partner in the pharmaceutical industry. Kilitch's product offerings are strategically curated to cater to a broad spectrum of medical requirements. The company specializes in sterile formulations, offering a wide range of injectable products including liquid and powder forms. These formulations are vital for delivering medications directly into the bloodstream, ensuring rapid and effective treatment. In addition to injectables, Kilitch provides advanced nasal delivery systems, enabling targeted administration of drugs through the nasal passages. Kilitch’s product line extends further to include topical formulations, addressing skin and surface-level ailments. This multi-faceted approach allows Kilitch to contribute to diverse therapeutic areas, strengthening its impact on global healthcare. Kilitch Drugs India Ltd. actively pursues opportunities for international expansion, strategically establishing its presence in key markets across the globe. By building strong distribution networks and fostering collaborations with local partners, Kilitch is successfully extending the reach of its pharmaceutical products. The company’s commitment to providing affordable, high-quality medications aligns with the growing demand for accessible healthcare solutions worldwide. Kilitch Drugs is poised to capitalize on emerging market trends and expanding its global footprint through strategic partnerships and a focus on product innovation. As Kilitch continues to evolve and grow, the company will maintain its unwavering commitment to improving patient outcomes.

Company Details

Symbol:KILITCH
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mukund Prataprai Mehta B.Com., LL.B.
Executive Chairman & MD
Ms. Mira Bhavin Mehta
MD & Director
Mr. Bhavin Mukund Mehta B.Pharm.
Whole-time Director

KILITCH Share Price: Frequently Asked Questions

What is the current share price of Kilitch Drugs (India) Limited?

Kilitch Drugs (India) Limited (KILITCH) trades at ₹188.82 on NSE and BSE. Market cap ₹660.14 (Cr). Educational data only.

What is the P/E ratio of Kilitch Drugs (India) Limited?

Kilitch Drugs (India) Limited has a P/E of 15.06x vs industry average 34.89x.

What is the Bull Run score for Kilitch Drugs (India) Limited?

Kilitch Drugs (India) Limited has a Bull Run score of 72.6/100 based on 25+ financial parameters.

Does Kilitch Drugs (India) Limited pay dividends?

Kilitch Drugs (India) Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Kilitch Drugs (India) Limited?

Kilitch Drugs (India) Limited has ROE of 12.52%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Kilitch Drugs (India) Limited?

Kilitch Drugs (India) Limited has debt-to-equity of 0.32.

Is Kilitch Drugs (India) Limited a good investment?

Bull Run gives Kilitch Drugs (India) Limited a score of 72.6/100. This is not investment advice — consult a SEBI-registered advisor.